IP Library › Granted Patent US 10,822,353

Granted Patent B2

US 10,822,353 · App. 16/333,577 · Granted Nov 3, 2020

Dithio ETP derivatives

Inventors: Sangkil Nam (Tujunga, CA); David Horne (Altadena, CA); Larry Eugene Overman (Corona Del Mar, CA); Brad Loertscher (Portage, MI)

Assignees: CITY OF HOPE; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

C07D513/18 A61K31/548 A61K31/706 A61K45/06 A61P35/00 C07D401/12 C07D487/04 C07D513/08

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,822,353
App. No.: 16/333,577
Granted: Nov 3, 2020
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed herein, inter alia, are compositions and methods of using the same for the treatment of cancer.

Claims (106)

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 1A , —NR 1B R 1C , —C(O)OR 1A , —C(O)NR 1B R 1C , —NO 2 , —SR 1D , —S(O) n1 R 1B , —SO v1 NR 1B R 1C , —NHNR 1B R 1C , —ONR 1B R 1C , —NHC(O)NHNR 1B R 1C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 2 is hydrogen, —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —COOR 2A , —CONR 2B R 2C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 3 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 3A , —NR 3B R 3C , —COOR 3A , —CONR 3B R 3C , —NO 2 , —SR 3D , —SO n3 R 3B , —SO v3 NR 3B R 3C , —NHNR 3B R 3C , —ONR 3B R 3C , —NHC(O)NHNR 3B R 3C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 4 is —C(O)-L 1 -R 18 or —C(S)-L 1 -R 18 ;

R 5 is —C(O)-L 2 -R 19 or —C(S)-L 2 -R 19 ; or

R 4 and R 5 may optionally be joined to form

L 1 is a bond, —O—, —NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene;

L 2 is a bond, —O—, —NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene;

R 18 and R 19 are independently halogen, substituted or unsubstituted C 1 -C 3 alkyl, substituted or unsubstituted aryl;

R 25 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 25A , —NR 25B R 25C , —C(O)OR 25A , —C(O)NR 25B R 25C , —NO 2 , —SR 25D , —S(O) n25 R 25B , —SO v25 NR 25B R 25C , —NHNR 25B R 25C , ONR 25B R 25C , —NHC(O)NHNR 25B R 25C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1A , R 1B , R 1C , R 1D , R 2A , R 2B , R 2C , R 3A , R 3B , R 3C , R 3D , R 25A , R 25B , R 25C , and R 25D are independently hydrogen, halogen, —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)—OH, —NHOH, —OCF 3 , —OCCl 3 , —OCBr 3 , —OCI 3 , —OCHF 2 , —OCHCl 2 , —OCHBr 2 , —OCHI 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R 1B and R 1C , R 2B and R 2C , R 3B and R 3C , and R 25B and R 25C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;

z3 is an integer from 0 to 5;

n1, n3, and n25 are independently an integer from 0 to 4; and

v1, v3, and v25 are independently 1 or 2.

2. The compound of claim 1 , wherein the compound has the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

X 1 is N or CR 10 ;

X 2 is N or CR 11 ;

X 3 is N or CR 12 ;

R 6 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 6A , —NR 6B R 6C , —COOR 6A , —CONR 6B R 6C , —NO 2 , —SR 6D , —SO n6 R 6B , —SO v6 NR 6B R 6C , —NHNR 6B R 6C , —ONR 6B R 6C , —NHC(O)NHNR 6B R 6C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 7 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 7A , —NR 7B R 7C , —COOR 7A , —CONR 7B R 7C , —NO 2 , —SR 7D , —SO n7 R 7B , —SO v7 NR 7B R 7C , —NHNR 7B R 7C , —ONR 7B R 7C , —NHC(O)NHNR 7B R 7C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 10 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 10A , —NR 10B R 10C , —COOR 10A , —CONR 10B R 10C , —NO 2 , —SR 10D , —SO n10 R 10B , —SO v10 NR 10B R 10C , —NHNR 10B R 10C , —ONR 10B R 10C , —NHC(O)NHNR 10B R 10C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 11 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 11A , —NR 11B R 11C , —COOR 11A , —CONR 11B R 11C , —NO 2 , —SR 11D , —SO n11 R 11B , —SO v11 NR 11B R 11C , —NHNR 11B R 11C , —ONR 11B R 11C , —NHC(O)NHNR 11B R 11C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 10 and R 11 may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl;

R 12 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 12A , —NR 12B R 12C , —COOR 12A , —CONR 12B R 12C , —NO 2 , —SR 12D , —SO n12 R 12B , —SO v12 NR 12B R 12C , —NHNR 12B R 12C , —ONR 12B R 12C , —NHC(O)NHNR 12B R 12C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 11 and R 12 may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl;

R 6A , R 6B , R 6C , R 6D , R 7A , R 7B , R 7C , R 7D , R 10A , R 10B , R 10C , R 10D , R 11A , R 11B , R 11C , R 11D , R 12A , R 12B , R 12C , and R 12D are independently hydrogen, halogen, —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)—OH, —NHOH, —OCF 3 , —OCCl 3 , —OCBr 3 , —OCI 3 , —OCHF 2 , —OCHCl 2 , —OCHBr 2 , —OCHI 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R 6B and R 6C , R 7B and R 7C , R 10B and R 10C , R 11B and R 11C , and R 12B and R 12C , substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;

n6, n7, n10, n11 and n12 are independently an integer from 0 to 4; and

v6, v7, v10, v11 and v12, are independently 1 or 2.

3. The compound of claim 2 , wherein the compound has structural formula:

wherein:

R 1.1 is hydrogen, halogen, —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —COOR 1.1A , —CONR 1.1B R 1.1C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1.2 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 1.2A , —NR 1.2B R 1.2C , —COOR 1.2A , —CONR 1.2B R 1.2C , —NO 2 , —SR 1.2D , —SO n1.2 R 1.2B , —SO v1.2 NR 1.2B R 1.2C , —NHNR 1.2B R 1.2C , —ONR 1.2B R 1.2C , —NHC(O)NHNR 1.2B R 1.2C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1.3 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 1.3A , —NR 1.3B R 1.3C , —COOR 1.3A , —CONR 1.3B R 1.3C , —NO 2 , —SR 1.3D , —SO n1.3 R 1.3B , —SO v1.3 NR 1.3B R 1.3C , —NHNR 1.3B R 1.3C , —ONR 1.3B R 1.3C , —NHC(O)NHNR 1.3B R 1.3C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1.4 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 1.4A , —NR 1.4B R 1.4C , —COOR 1.4A , —CONR 1.4B R 1.4C , —NO 2 , —SR 1.4D , —SO n1.4 R 1.4B , —SO v1.4 NR 1.4B R 1.4C , —NHNR 1.4B R 1.4C , —ONR 1.4B R 1.4C , —NHC(O)NHNR 1.4B R 1.4C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1.5 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 1.5A , —NR 1.5B R 1.5C , —COOR 1.5A , —CONR 1.5B R 1.5C , —NO 2 , —SR 1.5D , —SO n1.5 R 1.5B , —SO v1.5 NR 1.5B R 1.5C , —NHNR 1.5B R 1.5C , —ONR 1.5B R 1.5C , —NHC(O)NHNR 1.5B R 1.5C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1.1A , R 1.1B , R 1.1C , R 1.2A , R 1.2B , R 1.2C , R 1.2D , R 1.3A , R 1.3B , R 1.3C , R 1.3D , R 1.4A , R 1.4B , R 1.4C , R 1.4D , R 1.5A , R 1.5B , R 1.5C , and R 1.5D are independently hydrogen, halogen, —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)—OH, —NHOH, —OCF 3 , —OCCl 3 , —OCBr 3 , —OCI 3 , —OCHF 2 , —OCHCl 2 , —OCHBr 2 , —OCHI 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R 1.1B and R 1.1C , R 1.2B and R 1.2C , R 1.3B and R 1.3C , R 1.4B and R 1.4C , and R 1.5B and R 1.5C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;

n1.2, n1.3, n1.4, and n1.5 are independently an integer from 0 to 4; and

v1.2, v1.3, v1.4, and v1.5 are independently 1 or 2.

4. The compound of claim 3 , wherein the compound has structural formula:

5. The compound of claim 2 , wherein R 10 and R 11 or R 11 and R 12 are optionally joined to form a substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl having structural formula:

wherein:

X 6 is O, NR 23A , or S;

X 7 is O, NR 24A , or S;

z4 is an integer from 0 to 2;

z5 is an integer from 0 to 8;

m is 1 or 2;

R 21 , R 22 , R 23A , and R 24A are independently hydrogen, halogen,

—N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl 3 , —OCF 3 , —OCBr 3 , —OCI 3 , —OCHCl 2 , —OCHBr 2 , —OCHI 2 , —OCHF 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

6. The compound of claim 3 , wherein the compound has the formula:

7. The compound of claim 5 , wherein the compound has the formula:

8. The compound of claim 7 , wherein the compound has the formula:

9. The compound of claim 5 , wherein the compound has the formula:

10. The compound of claim 9 , wherein the compound has formula:

11. The compound of claim 5 , wherein the compound has the formula:

12. The compound of claim 11 , wherein the compound has formula:

13. The compound of claim 1 , wherein the compound has structural formula:

wherein:

X 4 is N or CR 13 ;

X 5 is CR 14 R 15 , S, O, or NR 20A ;

R 8 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 ,

—CI 3 , —CN, —CHO, —OR 8A , —NR 8B R 8C , —COOR 8A , —CONR 8B R 8C , —NO 2 , —SR 8D , —SO n8 R 8B , —SO v8 NR 8B R 8C , —NHNR 8B R 8C , —NHNR 8B R 8C , —ONR 8B R 8C , —NHC(O)NHNR 8B R 8C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 9 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 ,

—CI 3 , —CN, —CHO, —OR 9A , —NR 9B R 9C , —COOR 9A , —CONR 9B R 9C , —NO 2 , —SR 9D , —SO n9 R 9B , —SO v9 NR 9B R 9C , —NHNR 9B R 9C , —ONR 9B R 9C , —NHC(O)NHNR 9B R 9C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 13 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 13A , —NR 13B R 13C , —COOR 13A , —CONR 13B R 13C , —NO 2 , —SR 13D , —SO n13 R 13B , —SO v13 NR 13B R 13C , —NHNR 13B R 13C , —ONR 13B R 13C , —NHC(O)NHNR 13B R 13C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 14 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 14A , —NR 14B R 14C , —COOR 14A , —CONR 14B R 14C , —NO 2 , —SR 14D , —SO n14 R 14B , —SO v14 NR 14B R 14C , —NHNR 14B R 14C , —ONR 14B R 14C , —NHC(O)NHNR 14B R 14C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 15 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 15A , —NR 15B R 15C , —COOR 15A , —CONR 15B R 15C , —NO 2 , —SR 15D , —SO n15 R 15B , —SO v15 NR 15B R 15C , —NHNR 15B R 15C , —ONR 15B R 15C , —NHC(O)NHNR 15B R 15C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1.1A , R 1.1B , R 1.1C , R 1.2A , R 1.2B , R 1.2C , R 1.2D , R 1.3A , R 1.3B , R 1.3C , R 1.3D , R 8A , R 8B , R 8C , R 8D , R 9A , R 9B , R 9C , R 9D , R 13A , R 13B , R 13C , R 13D , R 14A , R 14B , R 14C , R 14D , R 15A , R 15B , R 15C , R 15D , and R 20A are independently hydrogen, halogen, —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)—OH, —NHOH, —OCF 3 , —OCCl 3 , —OCBr 3 , —OCI 3 , —OCHF 2 , —OCHCl 2 , —OCHBr 2 , —OCHI 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R 1.1B and R 1.1C , R 1.2B and R 1.2C , R 1.3B and R 1.3C , R 13B and R 13C , R 14B and R 14C , and R 15B and R 15C , substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;

n1.2, n1.3, n8, n9, n13, n14, and n15 are independently an integer from 0 to 4; and

v1.2, v1.3, v8, v9, v13, v14, and v15 are independently 1 or 2.

14. The compound of claim 13 , wherein the compound has formula:

15. The compound of claim 2 , wherein R 6 and R 7 independently hydrogen, X 2 is N, and R 12 is —OCH 3 .

16. The compound of claim 3 , wherein R 1.2 is substituted or unsubstituted C 1 -C 3 alkyl and R 1.3 is —CN.

17. The compound of claim 1 , wherein:

R 4 is —C(O)-L 1 -R 18 or —C(S)-L 1 -R 18 ; and

R 5 is —C(O)-L 2 -R 19 or —C(S)-L 2 -R 19 .

18. The compound of claim 1 , wherein L 1 and L 2 are independently —O—, —NH—, or a bond.

19. The compound of claim 1 , wherein:

L 1 is -L 1A -L 1B -, wherein L 1A is bonded to —C(O)— or —C(S)—; and

L 2 is -L 2A -L 2B -, wherein L 2A is bonded to —C(O)— or —C(S)—;

L 1A is a bond or —(CH 2 ) z1 —;

L 1B is a bond, —O— or —NR 16B —;

L 2A is a bond or —(CH 2 ) z2 —;

L 2B is a bond, —O— or —NR 17B —;

z1 and z2 are independently an integer from 1 to 10; and

R 16B and R 17B are independently hydrogen or substituted or unsubstituted alkyl.

20. The compound of claim 1 , wherein R 18 and R 19 are independently unsubstituted C 1 -C 3 alkyl, unsubstituted aryl, or halogen.

21. The compound of claim 1 , wherein R 4 and R 5 are joined together to form:

22. The compound of claim 1 , wherein R 2 is methyl.

23. The compound of claim 1 , wherein the compound has the structure:

24. A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , wherein the cancer is lymphoma, melanoma, prostate cancer, or lung cancer.

25. The method of claim 24 , further comprising administering at least one additional anticancer agent, wherein the additional anticancer agent comprises an epigenetic inhibitor or a multi-kinase inhibitor.

26. The method of claim 25 , wherein the epigenetic inhibitor is azacitidine or decitadine.

27. The method of claim 25 , wherein the multi-kinase inhibitor is sorafenib.

28. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

29. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a combination of a compound of claim 1 and at least one additional anticancer agent, wherein the at least one additional anticancer agent comprises a multi-kinase inhibitor or an epigenetic inhibitor.

30. The pharmaceutical composition of claim 29 , wherein the multi-kinase inhibitor is sorafenib and the epigenetic inhibitor is azacitidine or decitabine.

31. The pharmaceutical composition of claim 28 for use in the method of treating solid or blood tumor, said method comprising administering to a subject in need thereof the pharmaceutical composition of claim 28 , wherein the solid or blood tumor is lung cancer, lymphoma, melanoma, or prostate cancer.

32. A method of inhibiting the growth of a cancer cell, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , wherein the cancer cell is lymphoma cell, melanoma cell, lung cancer cell, or prostate cancer cell.

33. The method of claim 24 , wherein lymphoma is cutaneous T-cell lymphoma.

34. The method of claim 32 , where the lymphoma cell is cutaneous T-cell lymphoma cell.

Assignments (5)

CONFIRMATORY LICENSE Recorded Oct 12, 2022

From: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE

To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT

Reel/Frame 061655/0675 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2019

From: NAM, SANGKIL; HORNE, DAVID

To: CITY OF HOPE

Reel/Frame 050138/0743 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2019